REVOLUTION MEDICINES INC (RVMD) Stock Price & Overview

NASDAQ:RVMDUS76155X1000

Current stock price

94.86 USD
-0.21 (-0.22%)
At close:
96 USD
+1.14 (+1.2%)
After Hours:

The current stock price of RVMD is 94.86 USD. Today RVMD is down by -0.22%. In the past month the price decreased by -2.54%. In the past year, price increased by 142.48%.

RVMD Key Statistics

52-Week Range29.17 - 124.49
Current RVMD stock price positioned within its 52-week range.
1-Month Range94.67 - 107.45
Current RVMD stock price positioned within its 1-month range.
Market Cap
18.798B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-5.91
Dividend Yield
N/A

RVMD Stock Performance

Today
-0.22%
1 Week
-3.60%
1 Month
-2.54%
3 Months
+20.20%
Longer-term
6 Months +103.78%
1 Year +142.48%
2 Years +194.32%
3 Years +337.95%
5 Years +106.76%
10 Years N/A

RVMD Stock Chart

REVOLUTION MEDICINES INC / RVMD Daily stock chart

RVMD Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 96.11% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RVMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RVMD. The financial health of RVMD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RVMD Earnings

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$1.86
Revenue Reported
EPS Surprise -15.36%
Revenue Surprise -100.00%

RVMD Forecast & Estimates

27 analysts have analysed RVMD and the average price target is 124.38 USD. This implies a price increase of 31.12% is expected in the next year compared to the current price of 94.86.

For the next year, analysts expect an EPS growth of -26.4% and a revenue growth 966.48% for RVMD


Analysts
Analysts87.41
Price Target124.38 (31.12%)
EPS Next Y-26.4%
Revenue Next Year966.48%

RVMD Groups

Sector & Classification

RVMD Financial Highlights

Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS decreased by -65.55% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.13B
Industry RankSector Rank
PM (TTM) N/A
ROA -48.05%
ROE -69.35%
Debt/Equity 0.16
Chartmill High Growth Momentum
EPS Q2Q%-66.07%
Sales Q2Q%N/A
EPS 1Y (TTM)-65.55%
Revenue 1Y (TTM)N/A

RVMD Ownership

Ownership
Inst Owners100.47%
Shares198.17M
Float190.54M
Ins Owners1.82%
Short Float %7.17%
Short Ratio3.72

RVMD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8388.432B
AMGN AMGEN INC16.04197.413B
GILD GILEAD SCIENCES INC16.4179.993B
VRTX VERTEX PHARMACEUTICALS INC24.21119.226B
REGN REGENERON PHARMACEUTICALS15.9578.843B
ALNY ALNYLAM PHARMACEUTICALS INC42.0141.564B
INSM INSMED INC N/A30.069B
BIIB BIOGEN INC11.2926.644B
NTRA NATERA INC N/A26.624B
UTHR UNITED THERAPEUTICS CORP17.9523.498B
MRNA MODERNA INC N/A20.758B
EXAS EXACT SCIENCES CORP340.7419.77B

About RVMD

Company Profile

RVMD logo image Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Company Info

IPO: 2020-02-13

REVOLUTION MEDICINES INC

700 Saginaw Dr

Redwood City CALIFORNIA 94063 US

CEO: Mark A. Goldsmith

Employees: 883

RVMD Company Website

RVMD Investor Relations

Phone: 13026365400

REVOLUTION MEDICINES INC / RVMD FAQ

What does REVOLUTION MEDICINES INC do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).


What is the current price of RVMD stock?

The current stock price of RVMD is 94.86 USD. The price decreased by -0.22% in the last trading session.


Does REVOLUTION MEDICINES INC pay dividends?

RVMD does not pay a dividend.


What is the ChartMill technical and fundamental rating of RVMD stock?

RVMD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Would investing in REVOLUTION MEDICINES INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RVMD.


Can you provide the market cap for REVOLUTION MEDICINES INC?

REVOLUTION MEDICINES INC (RVMD) has a market capitalization of 18.80B USD. This makes RVMD a Large Cap stock.


Can you provide the ownership details for RVMD stock?

You can find the ownership structure of REVOLUTION MEDICINES INC (RVMD) on the Ownership tab.